Owing to the mechanism by which MGMT repairs O6-methylguanine adducts and is subsequently degraded, the use of alternative dosing regimens is an appealing method to enhance temzolomide mediated tumour cytotoxicity. The gene discussed is MGMT; the disease is neoplasm.